CZ20031349A3 - Kombinační léčba nemocí závislých na estrogenech - Google Patents

Kombinační léčba nemocí závislých na estrogenech Download PDF

Info

Publication number: CZ20031349A3
Authority: CZ; Czechia
Prior art keywords: cancer; lhrh agonist; triptorelin; aromatase inhibitor; exemestane
Prior art date: 2000-11-16

Application number

CZ20031349A

Other languages

Czech (cs)

English (en)

Inventor

Purandareádinesh

Original Assignee

Pharmaciaá@Áupjohnácompany

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-16

Filing date

2001-11-06

Publication date

2004-05-12

2001-11-06 Application filed by Pharmaciaá@Áupjohnácompany filed Critical Pharmaciaá@Áupjohnácompany

2004-05-12 Publication of CZ20031349A3 publication Critical patent/CZ20031349A3/cs

Links

230000001419 dependent effect Effects 0.000 title claims abstract description 25
229940011871 estrogen Drugs 0.000 title claims abstract description 8
239000000262 estrogen Substances 0.000 title claims abstract description 8
238000011282 treatment Methods 0.000 title claims description 26
201000010099 disease Diseases 0.000 title description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
239000003886 aromatase inhibitor Substances 0.000 claims abstract description 37
229940122815 Aromatase inhibitor Drugs 0.000 claims abstract description 36
206010028980 Neoplasm Diseases 0.000 claims abstract description 31
241000124008 Mammalia Species 0.000 claims abstract description 11
229940088597 hormone Drugs 0.000 claims abstract description 9
239000005556 hormone Substances 0.000 claims abstract description 9
230000002401 inhibitory effect Effects 0.000 claims abstract description 4
239000000556 agonist Substances 0.000 claims description 47
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 45
102100024028 Progonadoliberin-1 Human genes 0.000 claims description 45
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 45
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 45
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 30
238000000034 method Methods 0.000 claims description 29
208000026310 Breast neoplasm Diseases 0.000 claims description 22
201000011510 cancer Diseases 0.000 claims description 22
229960004824 triptorelin Drugs 0.000 claims description 22
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 22
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 21
206010006187 Breast cancer Diseases 0.000 claims description 21
229960000255 exemestane Drugs 0.000 claims description 21
239000003163 gonadal steroid hormone Substances 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 16
108010069236 Goserelin Proteins 0.000 claims description 14
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical group C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 13
229960002913 goserelin Drugs 0.000 claims description 13
239000003112 inhibitor Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 13
239000005557 antagonist Substances 0.000 claims description 12
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 11
229960004421 formestane Drugs 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 9
108010000817 Leuprolide Proteins 0.000 claims description 9
230000009286 beneficial effect Effects 0.000 claims description 9
229950011548 fadrozole Drugs 0.000 claims description 9
-1 fonnestane Chemical compound 0.000 claims description 9
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 9
229960004338 leuprorelin Drugs 0.000 claims description 9
ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 claims description 8
206010033128 Ovarian cancer Diseases 0.000 claims description 8
230000002611 ovarian Effects 0.000 claims description 8
229960000294 triptorelin pamoate Drugs 0.000 claims description 8
229960001771 vorozole Drugs 0.000 claims description 8
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 claims description 8
201000009030 Carcinoma Diseases 0.000 claims description 7
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
102000014654 Aromatase Human genes 0.000 claims description 6
108010078554 Aromatase Proteins 0.000 claims description 6
229960002932 anastrozole Drugs 0.000 claims description 6
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
108010023617 abarelix Proteins 0.000 claims description 5
AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 5
229960002184 abarelix Drugs 0.000 claims description 5
239000003405 delayed action preparation Substances 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229960003881 letrozole Drugs 0.000 claims description 5
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 5
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
108010037003 Buserelin Proteins 0.000 claims description 3
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
229960002719 buserelin Drugs 0.000 claims description 3
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 claims description 2
HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 2
PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 claims description 2
108700013943 AN 207 Proteins 0.000 claims description 2
229940126062 Compound A Drugs 0.000 claims description 2
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
108700029108 MI 1544 Proteins 0.000 claims description 2
108010021717 Nafarelin Proteins 0.000 claims description 2
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
206010057644 Testis cancer Diseases 0.000 claims description 2
208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
108010070670 antarelix Proteins 0.000 claims description 2
229950010887 avorelin Drugs 0.000 claims description 2
108700008462 cetrorelix Proteins 0.000 claims description 2
229960003230 cetrorelix Drugs 0.000 claims description 2
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
108700025485 deslorelin Proteins 0.000 claims description 2
229960005408 deslorelin Drugs 0.000 claims description 2
108700032141 ganirelix Proteins 0.000 claims description 2
GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 2
229960003794 ganirelix Drugs 0.000 claims description 2
239000002474 gonadorelin antagonist Substances 0.000 claims description 2
239000000017 hydrogel Substances 0.000 claims description 2
230000002163 immunogen Effects 0.000 claims description 2
239000007943 implant Substances 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000020816 lung neoplasm Diseases 0.000 claims description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
229960002333 nafarelin Drugs 0.000 claims description 2
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
108010092834 ramorelix Proteins 0.000 claims description 2
229950000277 ramorelix Drugs 0.000 claims description 2
201000003120 testicular cancer Diseases 0.000 claims description 2
229950011372 teverelix Drugs 0.000 claims description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
206010046766 uterine cancer Diseases 0.000 claims description 2
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 2
125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims 1
201000008275 breast carcinoma Diseases 0.000 claims 1
230000000415 inactivating effect Effects 0.000 claims 1
208000016035 malignant germ cell tumor of ovary Diseases 0.000 claims 1
201000008042 ovarian germ cell cancer Diseases 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
238000002648 combination therapy Methods 0.000 abstract description 3
210000001672 ovary Anatomy 0.000 abstract description 2
210000001550 testis Anatomy 0.000 abstract description 2
230000015572 biosynthetic process Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000002280 anti-androgenic effect Effects 0.000 description 4
239000000051 antiandrogen Substances 0.000 description 4
208000035269 cancer or benign tumor Diseases 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
229940046836 anti-estrogen Drugs 0.000 description 3
230000001833 anti-estrogenic effect Effects 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
239000000328 estrogen antagonist Substances 0.000 description 3
241001132374 Asta Species 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
238000009806 oophorectomy Methods 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
201000005825 prostate adenocarcinoma Diseases 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
206010057654 Breast cancer female Diseases 0.000 description 1
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
239000003098 androgen Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
201000003115 germ cell cancer Diseases 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000647 testicular hormone Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CZ20031349A 2000-11-16 2001-11-06 Kombinační léčba nemocí závislých na estrogenech CZ20031349A3 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71460500A	2000-11-16	2000-11-16

Publications (1)

Publication Number	Publication Date
CZ20031349A3 true CZ20031349A3 (cs)	2004-05-12

Family

ID=24870727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20031349A CZ20031349A3 (cs)	2000-11-16	2001-11-06	Kombinační léčba nemocí závislých na estrogenech

Country Status (16)

Country	Link
EP (1)	EP1341549A2 (pl)
JP (1)	JP2004536022A (pl)
KR (1)	KR20030051828A (pl)
CN (1)	CN1498112A (pl)
AU (1)	AU2002230464A1 (pl)
BR (1)	BR0115423A (pl)
CA (1)	CA2428249A1 (pl)
CZ (1)	CZ20031349A3 (pl)
EA (1)	EA200300572A1 (pl)
IL (1)	IL155817A0 (pl)
MX (1)	MXPA03004195A (pl)
NO (1)	NO20032206L (pl)
NZ (1)	NZ525720A (pl)
PL (1)	PL365904A1 (pl)
WO (1)	WO2002039995A2 (pl)
ZA (1)	ZA200303669B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL153218A0 (en)	2000-06-02	2003-07-06	Univ Texas	Ethylenedicysteine (ec) -drug conjugates
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) *	2005-04-02	2005-05-11	Medical Res Council	Combination treatment methods
EP1891964A1 (en) *	2006-08-08	2008-02-27	AEterna Zentaris GmbH	Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20080261933A1 (en) *	2007-04-23	2008-10-23	Jens Hoffmann	Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
CN101775054B (zh) *	2010-02-05	2012-12-26	常州佳尔科药业集团有限公司	4-羟基-4-烯-3-酮甾族化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9911582D0 (en) *	1999-05-18	1999-07-21	Pharmacia & Upjohn Spa	Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) *	1999-12-30	2000-02-16	Pharmacia & Upjohn Spa	Process for treating gynecomastia

2001
- 2001-11-06 KR KR10-2003-7006608A patent/KR20030051828A/ko not_active Withdrawn
- 2001-11-06 EA EA200300572A patent/EA200300572A1/ru unknown
- 2001-11-06 CZ CZ20031349A patent/CZ20031349A3/cs unknown
- 2001-11-06 AU AU2002230464A patent/AU2002230464A1/en not_active Abandoned
- 2001-11-06 BR BR0115423-0A patent/BR0115423A/pt not_active IP Right Cessation
- 2001-11-06 NZ NZ525720A patent/NZ525720A/en unknown
- 2001-11-06 PL PL01365904A patent/PL365904A1/pl not_active Application Discontinuation
- 2001-11-06 MX MXPA03004195A patent/MXPA03004195A/es unknown
- 2001-11-06 IL IL15581701A patent/IL155817A0/xx unknown
- 2001-11-06 EP EP01990699A patent/EP1341549A2/en not_active Withdrawn
- 2001-11-06 CN CNA018189385A patent/CN1498112A/zh active Pending
- 2001-11-06 JP JP2002542370A patent/JP2004536022A/ja active Pending
- 2001-11-06 WO PCT/US2001/043847 patent/WO2002039995A2/en not_active Ceased
- 2001-11-06 CA CA002428249A patent/CA2428249A1/en not_active Abandoned
2003
- 2003-05-13 ZA ZA200303669A patent/ZA200303669B/en unknown
- 2003-05-15 NO NO20032206A patent/NO20032206L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20030051828A (ko)	2003-06-25
NO20032206L (no)	2003-07-15
JP2004536022A (ja)	2004-12-02
NO20032206D0 (no)	2003-05-15
NZ525720A (en)	2006-12-22
BR0115423A (pt)	2005-12-13
CN1498112A (zh)	2004-05-19
EP1341549A2 (en)	2003-09-10
AU2002230464A1 (en)	2002-05-27
CA2428249A1 (en)	2002-05-23
EA200300572A1 (ru)	2004-06-24
PL365904A1 (pl)	2005-01-10
IL155817A0 (en)	2003-12-23
MXPA03004195A (es)	2003-09-22
WO2002039995A9 (en)	2003-02-06
WO2002039995A2 (en)	2002-05-23
ZA200303669B (en)	2004-05-13
WO2002039995A3 (en)	2003-05-01

Publication	Publication Date	Title
Felberbaum et al.	1998	Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
EP0480950B1 (en)	1999-03-24	Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
EP3297631B1 (en)	2019-09-04	Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
MXPA04009455A (es)	2005-01-25	Aumento de produccion endogena de gonadotropina.
KR20100068287A (ko)	2010-06-22	폐경기 전 여성의 에스트로겐 의존성 질환의 치료
EP1377298B1 (en)	2006-08-30	Exemestane for treating hormono-dependent disorders
KR19990082080A (ko)	1999-11-15	부인과 질환을 치료하기 위한 lhrh 유사 물질 및 항에스트로겐을 포함하는 제약적 배합 제제
CZ20031349A3 (cs)	2004-05-12	Kombinační léčba nemocí závislých na estrogenech
CN1137722C (zh)	2004-02-11	为长期治疗方案确立基础(tonic)卵巢雌激素分泌
Klijn	1992	LH-RH agonists in the treatment of metastatic breast cancer: ten years’ experience
WO2002056903A2 (en)	2002-07-25	Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
WO2002039996A2 (en)	2002-05-23	Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
US20040043938A1 (en)	2004-03-04	Combination therapy for estrogen-dependent disorders
EP3784346A1 (en)	2021-03-03	A composition for treating one or more estrogen related diseases
HK1066169A (en)	2005-03-18	Combination therapy for estrogen-dependent disorders
Forti	1988	Clinicai applications of GnRH analogs
Ferguson et al.	2004	Current research on the use of hormonal therapy in the treatment of advanced or recurrent endometrial cancer
WO2025252544A1 (en)	2025-12-11	Male oral contraceptive
JP2019524846A (ja)	2019-09-05	子宮内膜症の治療のための投与レジメン
Sukcharoen	2000	GnRH antagonists: an update
KR100210472B1 (ko)	1999-07-15	황체형성 호르몬 분비 호르몬 길항 펩티드
HU199694B (en)	1990-03-28	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
TW200902029A (en)	2009-01-16	Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in BRCA mediated diseases
HK1014878A (en)	1999-10-08	Combinations for prophylaxsis and/or treatment of benign prostatic hyperplasia containing a 17 beta-hydroxy steroid dehydrogenase(17bhsd) inhibitor and at least one further active ingredient